Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease

 M.A.S. and M.I.P. are joint first authors.

 MAS: No conflicts to declare.

 MIP: Salary is part funded by the NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Trust and Imperial College London UK. He discloses receiving payment for advisory boards or lecturing from GlaxoSmithKline, Astra Zeneca, Chiesi, Novartis, PortAero and Broncus all of whom would have potential interest in using 6MWT as a study outcome and that his institution holds or has recently held on his behalf as Principal Investigator grants for COPD studies or for consultancy from GlaxoSmithKline, Astra Zeneca, PortAero, Novartis and the EU-IMI Proactive initiative.

 BC: Received grants to the pulmonary division he works in to complete research studies from GlaxoSmithKline, Boehringer-Ingelheim, Forrest Medical, AstraZeneca and Aeris. BC has served on advisory boards for GlaxosmithKline, Boehringer-Ingelheim, Almirall, AstraZeneca, Aeris and Deep Breeze, and has received speaker fees from GlaxosmithKline, Boehringer-Ingelheim, AstraZeneca, Almirall and Esteve.

 LDE: Employee and shareholder of GlaxoSmithKline.

 MLW: Employee and shareholder of GlaxoSmithKline.

 VPP: No conflicts to declare.

 JV: Received fees for advising and/or presenting from GlaxoSmithKline, Astra Zeneca, Pfizer, Boehringer-Ingelheim, Nycomed, Hofmann - la Roche, Talecris, Kamada and Sounds Biotech; has received research support from GlaxoSmithKline.

 PMAC: Received consulting fees from AstraZeneca, GlaxoSmithKline, Nycomed and Pfizer, speaking fees from GlaxoSmithKline and Nycomed, and grant support from Boehringer-Ingelheim and GlaxoSmithKline.

 RT-S: Employee and shareholder of GlaxoSmithKline.

 AA: Received reimbursements, fees, or funding from GlaxoSmithKline, Almirall, AstraZeneca, Boheringer-Ingelheim, Roche, Nycomed, Novartis and Procter & Gamble.

 HOC: Holds a GSK Clinical Scientist Award from GSK Canada but was a Canadian Institutes of Health Research/British Columbia Lung Association New Investigator during the time of this study. HOC has received an honorarium for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline. In addition, HOC was the co-investigator on two multi-center studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. HOC has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc. to measure changes in lung volume in subjects with severe emphysema. HOC is the co-investigator (D Sin PI) on a Canadian Institutes of Health - Industry (Wyeth) partnership grant, and has received a fee for speaking at a conference and related travel expenses from AstraZeneca (Australia).

 DAL: Received grant funding, honoraria and travel expenses from GlaxoSmithKline and serves on the Respiratory CEDD Board of GlaxoSmithKline.

 WM: Reimbursed for travel by GlaxoSmithKline, Zambon, Astra Zeneca, Boehringer-Ingelheim, Pfizer and Micromet for attending conferences; has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings; serves on advisory boards for GlaxoSmithKline, Pfizer, Almirall, Amgen, Bayer and Micromet; serves as a consultant for Pfizer and SMB Pharmaceuticals. SR: consulted or participated in advisory boards for Able Associates, Adelphia Research, Almirall/Prescott, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer-Ingelheim, Chiesi, CommonHealth, Consult Complete, COP Forum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Eaton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connection, M. Pankove, MedaCorp, MDRx Financial, Mpex, Novartis, Nycomed, Oriel Therapeutics, Otsuka, Pennside Partners, Pfizer (Varenicline), PharmaVentures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, Scimed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, VantagePoint Management.

 SR has given lectures for: American Thoracic Society, Astra Zeneca, Boehringer-Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, Information TV, Network for Continuing Ed, Novartis, Pfizer, SOMA. SR has received industry-sponsored grants from: Astra Zeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, Otsuka.

 EKS: Received grant support and consulting fees from GlaxoSmithKline for studies of COPD genetics and honoraria and consulting fees from Astra Zeneca.

 CC: Employee and shareholder of GlaxoSmithKline.

 JCY: Employee and shareholder of GlaxoSmithKline.

 EFMW: Serves on an advisory board for Nycomed. EFMW has received lecture fees from GlaxoSmithKline, AstraZeneca and Novartis, and has received research grants from GlaxoSmithKline and AstraZeneca.

 This article has an online depository, which is accessible from this issue’s table of contents.

 The ECLIPSE study is funded by GlaxoSmithKline. GlaxoSmithKline had a role in study design, data collection and analyses, decision to publish, and preparation of the manuscript.

 The trial's unique registration number: ClinicalTrials.gov with identifier NCT00292552.

PII: S1525-8610(11)00236-2

doi: 10.1016/j.jamda.2011.06.009

© 2012 American Medical Directors Association, Inc. Published by Elsevier Inc All rights reserved.